REGN Q2 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.5B+12.3% YoY

Gross Profit

$3.1B86.5% margin

Operating Income

$1.1B30.2% margin

Net Income

$1.4B40.4% margin

EPS (Diluted)

$12.41

QoQ Revenue Growth

+12.8%

Cash Flow

Operating Cash Flow

$354M

Free Cash Flow

$143M

Stock-Based Comp.

$223M

Balance Sheet

Total Assets

$36.1B

Total Liabilities

$7.9B

Stockholders' Equity

$28.2B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$3.2B	+12.3%
Gross Profit	$3.1B	$2.7B	+15.7%
Operating Income	$1.1B	$1.0B	+5.2%
Net Income	$1.4B	$968M	+47.9%

Revenue Segments

Product

$1.9B54%

Collaboration Revenue

$1.5B43%

Product and Service, Other

$105M3%